Ajanta Pharma zooms on getting USFDA`s final nod for Topiramate Extended-Release Capsules
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Ajanta Pharma is currently trading at Rs. 1782.60, up by 54.10 points or 3.13% from its previous closing of Rs. 1728.50 on the BSE.
The scrip opened at Rs. 1750.05 and has touched a high and low of Rs. 1800.00 and Rs. 1750.05 respectively. So far 26 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1804.70 on 17-Aug-2023 and a 52 week low of Rs. 1115.15 on 28-Oct-2022.
Last one week high and low of the scrip stood at Rs. 1800.00 and Rs. 1681.10 respectively. The current market cap of the company is Rs. 21764.52 crore.
The promoters holding in the company stood at 66.21%, while Institutions and Non-Institutions held 26.00% and 7.79% respectively.
Ajanta Pharma has received final approval from the United States Food and Drug Administration (USFDA) to market Topiramate Extended-Release Capsules, 25 mg, 50 mg, 100 mg and 200 mg. Topiramate is the generic version of Supernus Pharmaceuticals Inc’s Trokendi XR. As per the settlement with the innovator, Ajanta can launch Topiramate on February 1, 2026 or earlier under certain circumstances.
The company has received 50 final ANDA approvals, out of which 41 are commercialized. Ajanta also holds 2 tentative approvals and 22 ANDAs are awaiting USFDA approvals.
Ajanta Pharma is a specialty pharmaceutical company engaged in development, manufacturing and marketing of quality finished dosages.
